Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: Authorities have urged South Koreans to stay home and maintain social distancing, as imported cases and new outbreaks around small clusters continued to emerge while an overall tally in new infections has been declining. Restrictions on high-risk events such as religious, sports and entertainment gatherings took effect on Sunday, requiring facilities to ensure space between the attendees and allowing local governments to conduct on-site checks and issue fines. "Our fight against the virus is a three-legged race," President Moon Jae-in said on Sunday, referring to the need for the community to work in step with the government. "It doesn't matter even if you are not sick and doing well by yourself." Most churches have turned to online services over the past few weeks, but local media said there were several that pushed ahead with physical gatherings on Sunday, prompting scuffles with police and protests by residents calling for disbanding. At the Sarang Jeil Church in Seoul, several attendees tried to force out a dozen police officers, domestic newswire Yonhap reported. A video uploaded by a purported member of the church on YouTube showed a woman lying on the ground while another was heard shouting "Why are you doing this? Is this North Korea?" Yonhap quoted a city official as saying the church did not follow rules and ensure sufficient space among the attendees. Reuters was not immediately able to reach the police or the Seoul city government for comment and calls to the church for comment were unanswered. Elsewhere, Yonhap news photos showed a group of residents staging a rally in front of the Yonsei Central Baptist Church in Seoul, holding up a sign calling for a halt to services for the safety of neighbors. More than half of South Korea's cases were traced to a fringe Christian church in the hard-hit southeastern city of Daegu. This week, some 60 members of a Protestant church in Seongnam, south of Seoul, have also tested positive this week. The Korea Centers for Disease Control and Prevention (KCDC) reported 98 new coronavirus cases, bringing national infections to 8,897. The death toll rose by six to 110. The daily tally marked the 11th day in a row the country has posted new infections of around 100, compared with the peak of 909 cases recorded on Feb. 29. The KCDC renewed caution for overseas travelers on Sunday, after the government toughened border checks and imposed a two-week mandatory quarantine for all long-term arrivals from Europe due to a spike in returnee cases. At least 15 travelers tested positive on Saturday, the KCDC said, eight of them from Europe and three from the United States. Most of them were South Koreans. "We're implementing intensive social distancing over the next 15 days," KCDC deputy director Kwon Jun-wook said at a briefing. "After that, we will open schools and return to a regular life cycle in the face of the battle on the coronavirus." Claim: South Korean churchgoers scuffle with police as virus curbs on gatherings kick in.

Ex Output:
Members of a South Korean church scuffled with police on Sunday, media reported, as government restrictions on religious services and other gatherings due to the spread of the coronavirus took effect.

Ex Input:
Paragraph: Although the release doesn't give actual costs of warfarin versus some of the newer drugs, or factor in the cost of the usual monthly blood testing required of those taking the drug, it does note the cost of the gene testing used for the study, and that the $200 price tag is now less than a month's prescription of one of the newer anti-coagulants on the market. The release gives results in both actual numbers of patients and the percentage of reduction of adverse events in those given the genetic test and a comparison group. Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them. The release offers a good description of the design of the study. It was randomized and enrolled more than 1,600 older patients at high risk of blood clots following surgeries. The release explains that one group received warfarin dosing based on standard factors (age, height and weight) and the second group was dosed using these clinical factors plus their genetic variants. The release also offers a detailed breakdown on how many fewer side effects occurred among patients had genetic testing completed compared to those who didn't. No mongering here. Nicely done and quite complete. Although the release briefly mentions the availability of a "newer anticoagulant," it should have included a sentence or two about these newer injectable drugs and their overall risks and benefits in comparison to warfarin. It would also have been helpful to tell readers whether the genetic testing that appears to play a role in safer warfarin dosing would have clinical relevance for informing the use of the new blood thinners as well. The fact is that genetic testing is irrelevant for the newer anti-coagulants because they operate in a completely different manner. But all the blood thinners old and new carry the same risk of bleeding. The problem with warfarin is the variability in blood levels which requires frequent monitoring, hence the genetic tests to guide dosing. The careful reader will get it: testing for these genetic variants is still an experimental practice for the most part, and further testing of how the mutations affect warfarin is needed. But the release could have been more explicit in saying that no one is yet recommending genetic testing for millions of warfarin users. While the genetic tests are "available" in the sense that anyone can order them for the most part, they are not routinely used clinically and probably wouldn't be covered by insurance so in that sense they are not widely available to most people. The release describes how the genetic test used in the new study differs from previous similar studies. Overall the language is careful and contextual. The headline should have been toned back a bit to note that this is early research and more study is needed before concluding that "Genetic testing helps set safe dose of common blood thinner," as the headline now states. Claim: Genetic testing helps set safe dose of common blood thinner

Ex Output:
This news release describes results of a study designed to learn whether testing for the presence of three gene variants could make dosing with the blood thinner warfarin safer for patients given the drug to prevent blood clots after joint replacement surgery. The study found a modest reduction in the risk of bleeding or clots (from over- or under-dosing) in those whose regimens were developed in part by genetic testing for the variants, compared to those whose doses were calculated without the genetic testing. The release does an overall good job in describing the study, its purpose and design; and in quantifying the results. It could have been even stronger if it had included more information about newer alternatives to warfarin that are growing in use and an explicit statement that no one is yet recommending routine genetic testing for the variants based on this study. And although the headline somewhat over promises clinical benefit at this point in time, thoughtful readers will come away with a decent understanding of the context of the research and its potential impact. Some estimates put the number of Americans regularly taking the clot-preventing blood thinner warfarin and several newer anticoagulants at more than six million. Warfarin (sold under the brand name Coumadin) requires frequent blood testing to address risks of overdoses (and potentially lethal bleeding) and under-dosing (ineffective prevention of strokes and other blood clots). Because warfarin is cheap, and its effects are reversible with vitamin K, research designed to make it easier and safer for patients to take is likely to be highly newsworthy for them and their caregivers.

Ex Input:
Paragraph: Many areas of Saudi consumption, including the retail industry, housing and travel, have ballooned in the past decade because of oil-fuelled growth in national income. But healthcare has lagged, partly because of government inefficiency and bureaucracy. Now the mediocre quality of state-run healthcare has become a political liability for the government, especially in the wake of the 2011 uprisings elsewhere in the Arab world, which underlined the risks of social discontent. Many Saudis complain about overcrowded hospitals and shortages of medications. So the government has embarked on a drive to reform the sector, building hundreds of hospitals, providing interest-free loans to private companies and changing health insurance rules. This could make Saudi Arabia the world's fastest-growing major healthcare market over the next few years, helping to diversify the economy beyond oil and providing a bonanza to foreign companies selling medicines, equipment and services. "It is a case of chronic underinvestment and reactive overexpenditure," said Mohammad Kamal, an analyst at financial firm Arqaam Capital in Dubai. The standard of Saudi Arabian healthcare provision has long contrasted with its wealth. The kingdom, which the IMF ranked 30th in the world by GDP per capita for 2012, has 2.2 hospital beds per 1,000 residents, according to Arqaam, lower than the global average of 3.0 and far below the average of 5.5 in developed countries. Local newspapers routinely report complaints about issues such as overcrowding - with some patients receiving intravenous drips in hospital corridors - and poor hygiene and maintenance, resulting in pest infestations and infections. Abdulkarim al-Thobeiti, a Saudi engineer working in the public sector, says he will never set foot in a state-run hospital because they are either fully booked or poorly maintained. "If you want to make an appointment to see a doctor you have to wait for months, unless you have some connection or know someone who can pull a few strings," Thobeiti said. This may change as the government ramps up healthcare budgets. Spending has already jumped from $8 billion in 2008 to $27 billion last year, and Saudi asset management firm NCB Capital expects it to soar to $46 billion in 2017. In addition to building new state-run facilities, the government is offering private companies interest-free loans covering up to a half of the cost of building new hospitals. And, although the move has yet to be announced officially, Saudis employed in the public sector are expected to become eligible for state-funded health insurance within the next few years, Arqaam and other analysts say. This would enable them to use private healthcare services without paying extra fees out of their own pocket. Today, the overwhelming majority, about 83 percent, of Saudi Arabia's 8.4 million health insurance holders are expatriates whose employers are legally obliged to cover their insurance costs, according to Arqaam. The insurance reform could swell the pool with more than a million Saudi public servants and about 5 million of their dependents, Arqaam estimates. This implies a surge in demand for private Saudi healthcare firms, which are turning to the stock market to finance expansion. Sulaiman Al-Habib Medical Group and Almana General Hospitals will seek to list their shares on the local bourse in 2014 or early 2015, bankers told Reuters in November. Some companies have already tapped the market. Dallah Healthcare raised 540 million rials ($144 million) in an initial public offering of shares at the end of 2012, while National Medical Care Co conducted a 175 million rial IPO last March. Major global players are also looking for ways to boost their presence. General Electric (GE), one of the biggest manufacturers of medical equipment, has said it will build an assembly facility in Saudi Arabia. "Looking ahead at 2014, we continue to see a buoyant healthcare sector for the kingdom," said Mazen Dalati, chief executive of GE Healthcare in the country. The development of a private healthcare industry is good news for the Saudi government as it tries to diversify the economy and boost employment of citizens in the private sector to make the country less vulnerable to a big drop in oil prices. Higher state spending will not necessarily translate into quick improvements, however, as shown by the slow progress in the last few years of Saudi Arabia's $67 billion housing program, which was stalled by red tape and weak coordination between ministries. Analysts doubt in particular that the government will meet its own hospital construction targets. For private providers, human resources could become a bottleneck, especially if the government presses ahead with a plan to gradually replace foreign workers, who hold more than half the jobs in the sector, with Saudi nationals. Today, 20 percent of workers at healthcare companies are required to be Saudi citizens. The government is looking for ways to reduce the shortage of qualified personnel, including through partnerships with foreign firms such as GE. Reflecting such obstacles, healthcare firms' stock prices have lost steam since the post-IPO rallies commonly enjoyed by new Saudi listings. While the overall stock market has risen 16 percent since June, shares in Dallah are up just 11 percent, and National Medical Care has lost 8 percent. Future expansion of healthcare facilities, however, will be driven not just by increased government spending but also by fundamental factors such as the continuing growth of Saudi Arabia's young population and the high incidence of lifestyle-related diseases. One in every three people in the country is obese, according to the local Obesity Research Centre, whose researchers are looking into whether Saudis are genetically predisposed to the condition. "Saudi Arabia has an exceptionally high incidence of diabetes, heart disease and congenital disorders," said John Sfakianakis, chief investment strategist at Saudi investment firm MASIC. "The insurance sector changes will provide extra demand for sure." Claim: Saudi healthcare booms as state scrambles to close welfare gap.

Ex Output:
Stock market listings planned by two of Saudi Arabia's biggest private hospital operators point to a boom in its healthcare industry, as political pressures prompt the government to pour huge sums into the underdeveloped sector.